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The antiallograft immune response remains an 
important cause of acute rejection and late graft 
dysfunction in solid organ transplantation. In 
addition to the clinical and pathological mani-
festations of graft dysfunction, various biologi-
cal markers have been investigated to monitor 
graft rejection over the years. De novo donor-
specifi c anti-HLA antibodies represent a valu-
able marker, as their development is generally 
associated with rejection (1). However, T cell 
immunity plays a pivotal role in graft rejection (2). 
In this regard, a series of biological markers re-
lated to the infl ammatory response, such as cyto-
kines, thromboxane B2, β2 microglobulin (3, 4), 
and other phenotypic and functional markers 
associated with T cell activation such as IL-2Rα 
(CD25) expression, CD69, HLA-DR (5–8), 
cell prolifera tion, cytokine secretion, and cyto-
toxicity (9–12), have been eva luated to monitor 
cell-mediated immunity. However, these mark-
ers are nei ther sensitive nor specifi c, and their 
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It has been recently shown (Seddiki, N., B. Santner-Nanan, J. Martinson, J. Zaunders, 
S. Sasson, A. Landay, M. Solomon, W. Selby, S.I. Alexander, R. Nanan, et al. 2006. J. Exp. Med. 
203:1693–1700.) that the expression of interleukin (IL) 7 receptor (R) α discriminates 
between two distinct CD4 T cell populations, both characterized by the expression of CD25, 
i.e. CD4 regulatory T (T reg) cells and activated CD4 T cells. T reg cells express low levels of 
IL-7Rα, whereas activated CD4 T cells are characterized by the expression of IL-7Rαhigh. We 
have investigated the distribution of these two CD4 T cell populations in 36 subjects after 
liver and kidney transplantation and in 45 healthy subjects. According to a previous study 
(Demirkiran, A., A. Kok, J. Kwekkeboom, H.J. Metselaar, H.W. Tilanus, and L.J. van der Laan. 
2005. Transplant. Proc. 37:1194–1196.), we observed that the T reg CD25+CD45RO+IL-
7Rαlow cell population was reduced in transplant recipients (P < 0.00001). Interestingly, the 
CD4+CD25+CD45RO+IL-7Rαhigh cell population was signifi cantly increased in stable trans-
plant recipients compared with healthy subjects (P < 0.00001), and the expansion of this cell 
population was even greater in patients with documented humoral chronic rejection com-
pared with stable transplant recipients (P < 0.0001). The expanded CD4+CD25+CD45RO+IL-
7Rαhigh cell population contained allospecifi c CD4 T cells and secreted effector cytokines such 
as tumor necrosis factor α and interferon γ, thus potentially contributing to the mechanisms 
of chronic rejection. More importantly, CD4+IL-7Rα+and CD25+IL-7Rα+ cells were part of 
the T cell population infi ltrating the allograft of patients with a documented diagnosis of 
chronic humoral rejection. These results indicate that the CD4+CD25+IL-7Rα+ cell population 
may represent a valuable, sensitive, and specifi c marker to monitor allospecifi c CD4 T cell 
responses both in blood and in tissues after organ transplantation.
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measurement may be technically complex and time-consum-
ing. For these reasons, none of these markers is routinely used 
in the monitoring of trans plant recipients.
It has been recently reported that regulatory CD4 T cells 
(i.e., T reg cells) express low levels of IL-7Rα compared with 
other CD4 T cell subsets (13–17), and it has been proposed 
that IL-7Rα can be used to discriminate between T reg cells 
and activated CD4 T cells within the CD4+CD25+ cell pop-
ulation (15, 17). The CD4+CD25+IL-7Rαhigh cell popula-
tion contains activated T cells and is poorly represented (5% 
within CD4+CD25+ T cells) in healthy subjects. Conversely, 
after transplantation, both activated allospecifi c CD4 T cells 
and T reg cells may play a critical role by either participating 
in allograft rejection or promoting tolerance (18–25).
In this study, we have searched for sensitive and highly 
specifi c cellular markers that may defi ne the population of 
 allospecifi c CD4 T cells to quantify this cell population after 
transplantation, to monitor possible changes, and to determine 
the pattern of the allospecifi c population in chronic graft 
 rejection. We demonstrate that a CD4 T cell population 
 defi ned by the CD25+CD45RO+IL-7Rαhigh phenotype con-
tains allospecifi c cells and is expanded in the blood of stable 
transplant recipients and even further expanded in patients 
with a documented diagnosis of chronic rejection. In these 
latter patients, CD4+CD25+IL-7Rα+ cells were a major com-
ponent of T cells infi ltrating the allograft.
RESULTS AND D I S C U S S I O N 
Distribution of CD4+CD25+ T cell populations defi ned 
by the expression of IL-7R𝛂 (i.e., IL-7R𝛂low vs. IL-7R𝛂high) 
in stable organ transplant recipients
We have studied the distribution of T reg cells and activated 
CD4 T cells in blood mononuclear cells of 32 stable trans-
plant recipients, 21 liver and 11 kidney transplant recipients, 
and 4 patients with documented chronic kidney rejection, as 
well as 45 healthy subjects.
In accordance with recent studies (15, 17), the majority 
(88.2%) of CD4+CD25+ T cells were CD45RO+FOXP3+ 
and IL-7Rαlow in a representative healthy subject (1 out of 45), 
as shown in Fig. 1 A. This is the typical phenotype of T reg 
cells (26–28). Only a small percentage (3.1% in the example 
shown in Fig. 1 A) of CD4+CD25+ T cells expressed IL-
7Rαhigh, and these cells were FOXP3 negative. We then per-
formed the same analysis in stable transplant recipients. In one 
representative stable liver transplant recipient (1 out of 32), 
the CD4+CD25+CD45RO+FOXP3+IL-7Rαlow cell popu-
lation was reduced (66.1%; Fig. 1 A) compared with the rep-
resentative healthy subject. Interestingly, we observed a major 
increase (29.1%) in the CD4+CD25+CD45RO+FOXP3−IL-
7Rαhigh cell population (Fig. 1 A). The differences in 
the dis tribution of IL-7Rαlow and IL-7Rαhigh within the 
CD4+CD25+CD45RO+ cell population between healthy 
subjects and stable transplant recipients were confi rmed by the 
analysis of a larger number of subjects.
In agreement with a previous report (25), the percent-
age of total CD4+CD25+ T cells was signifi cantly reduced 
(P < 0.00001) in stable transplant recipients receiving im muno-
suppressive therapy compared with healthy subjects. The 
 reduction was in the range of 40%; the mean percentage of 
CD4+CD25+ T cells was 2.23 ± 0.12% in healthy subjects 
(n = 45) compared with 1.31 ± 0.14% in stable transplant 
recipients (n = 32; Fig. 1 B).
The analysis of IL-7Rα and FOXP3 expression allowed 
the discrimination between T reg cells (26–28) and activated 
CD4 T cells. This analysis showed that the percentage of 
T reg cells (the IL-7RαlowFOXP3+ cell population) was signifi -
cantly lower (P < 0.00001) in stable transplant recipients 
(mean = 62 ± 1.54%) compared with healthy subjects (mean = 
29.37 ± 2.33%; Fig. 1 B). Therefore, these results indicate 
that the reduction in T reg cells in stable transplant recipients 
is even greater than that estimated on the basis of the analysis 
of total CD4+CD25+ T cells. Furthermore, the population 
of activated CD4 T cells (i.e., the CD4+CD25+CD45RO+IL-
7Rαhigh cell population) was greatly expanded (mean = 18.38 ± 
1.05%) in stable transplant recipients compared with healthy 
donors (mean = 6.16 ± 0.76%; Fig. 1 B). These diff erences 
were highly signifi cant (P < 0.00001). On the basis of the 
present results and of recent studies (15, 17), we then analyzed 
the correlation between IL-7Rα and FOXP3 expression 
in CD4+CD25+ T cells in stable transplant recipients. This 
analysis confi rmed a negative correlation between IL-7Rα 
and FOXP3 expression in CD4+CD25+ T cells (Fig. 1 C). 
The IL-7Rαlow cells were contained within the FOXP3 pos-
itive cell population, whereas IL-7Rαhigh cells were within 
the FOXP3-negative cell population (Fig. 1 C). Collectively, 
these results indicated that IL-7Rα is a valuable marker to 
discriminate between T reg cells and activated CD4 T cells 
within the CD4+CD25+ T cell population in stable recipi-
ents of organ transplants.
Next, it was of interest to determine the suppressive ac-
tivity of CD4+CD25+CD45RO+IL-7Rαlow and IL-7Rαhigh 
cells. For these purposes, sorted purifi ed IL-7Rαlow and IL-
7Rαhigh cell populations isolated from stable transplant recip-
ients were assessed for their suppressive activity in a mixed 
lymphocyte reaction (MLR). The IL-7Rαlow cell population 
(T reg cells) strongly suppressed the MLR (83% inhibition of 
proliferation; P = 0.02), whereas the IL-7Rαhigh cell popula-
tion did not show any signifi cant suppressive activity (P = 
0.2; Fig. 1 D). These results obtained in stable transplant 
recipients are in agreement with those previously shown in 
healthy individuals (15, 17). Furthermore, the CD4+CD25+
CD45RO+IL-7Rαhigh cell population was also evaluated for 
the ability to secrete cytokines such as IFN-γ and TNF-α 
 after polyclonal stimulation with anti-CD3 plus anti-CD28 
antibodies. This analysis performed in blood mononuclear 
cells of 29 stable transplant recipients showed that a substan-
tial percentage of CD4+CD25+CD45RO+IL-7Rαhigh cells 
secreted infl ammatory cytokines, such as TNF-α (15%) 
and IFN-γ (4%), that may be involved in the mechanisms 
of chronic rejection (Fig. S1, http://www.jem.org/cgi/content/
full/jem.20062120/DC1). Collectively, these results indicated 
that the CD4+CD25+CD45RO+IL-7Rαhigh cell population 
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does not contain T reg cells and suggested that the expansion 
of this cell population in transplant recipients is associated 
with the presence of the allograft.
Larger expansion of the CD4+CD25+CD45RO+IL-7R𝛂high cell 
population in transplant recipients with chronic rejection
To better support this hypothesis, we examined the presence 
of the CD4+CD25+CD45RO+IL-7Rαhigh cell population in 
kidney transplant recipients with documented chronic humoral 
rejection. The total CD4+CD25+ T cell population was not sig-
nifi cantly diff erent in kidney recipients with documented chronic 
rejection compared with stable transplant recipients (P = 
0.21; Fig. 2 A). The percentage of CD4+CD25+FOXP3+ IL-
7Rαlow cells (i.e., the T reg cells) within the total CD4+CD25+ 
cell population was slightly reduced in patients with chronic 
rejection (51.07 ± 5.8%) compared with stable transplant re-
cipients (62.02 ± 1.54%; P = 0.01; Fig. 2 B). Interestingly, an 
almost doubled percentage of CD4+CD25+CD45RO+IL-
7Rαhigh cells within the total CD4+CD25+ cell population 
was observed in patients with documented chronic rejection as 
compared with stable transplant recipients (mean = 33.66 ± 
3.43% vs. 18.38 ± 1.05%; Fig. 2 C). These diff erences were 
highly signifi cant (P < 0.0001).
When the CD4+CD25+CD45RO+IL-7Rαhigh popula-
tion from patients with chronic rejection was compared with 
the one of stable kidney transplant recipients, the diff erence 
was also signifi cant (P = 0.0003; unpublished data). Therefore, 
Figure 1. Expression of CD25, CD45RO, IL-7R𝛂, and FOXP3 on 
blood CD4 T cells of healthy subjects and stable transplant recipients. 
Blood mononuclear cells from 45 healthy subjects and 32 stable organ 
transplant recipients (11 kidney and 21 liver transplant recipients) were 
analyzed for the surface expression of CD4, CD25, CD45RO, and IL-7Rα 
and for the intracellular expression of FOXP3. (A) Surface expression of 
CD45RO and IL-7Rα in CD4+CD25+ T cells. Representative fl ow cytometry 
profi les of one healthy donor (1 out of 45; top) and one stable liver trans-
plant recipient (1 out of 32; bottom). The vast majority of CD4+CD25+ 
T cells are CD45RO+IL-7Rαlow and FOXP3+ in the healthy donor, while a 
substantial percentage of CD4+CD25+ T cells are CD45RO+IL-7Rαhigh and 
FOXP3− (green) in the stable transplant recipient. (B) Cumulative data on 
the proportion of CD4+CD25+ T cells (top left), CD4+CD25+FOXP3+
IL-7Rαlow T cells (top right), and CD4+CD25+CD45RO+IL-7Rαhigh T cells 
(bottom) in stable transplant recipients and healthy donors. (C) Correlation 
between the expression of FOXP3 and IL-7Rα within CD4+CD25+ T cells. 
The percentage of FOXP3+ cells correlated with that of IL-7Rαlow cells 
within CD4+CD25+ T cells, and the percentage of FOXP3− cells correlated 
with that of IL-7Rαhigh cells within CD4+CD25+ T cells. The analyses were 
performed in 26 stable transplant recipients. In both cases, these correla-
tions were statistically signifi cant (P < 0.05). (D) Suppressive activity 
of IL-7Rαhigh and IL-7Rαlow CD4+CD25+CD45RO+ T cell populations 
in stable transplant recipients. CD4+CD25+CD45RO+IL-7Rαhigh and 
CD4+CD25+CD45RO+IL-7Rαlow cell populations were sorted from blood 
mononuclear cells of fi ve stable liver transplant recipients, and their sup-
pressive activity was evaluated in a MLR. The extent of cell proliferation in 
a MLR was assessed in the absence (positive control) or in presence of the 
sorted IL-7Rαlow and IL-7Rαhigh cell populations. Cell proliferation was 
measured by [3H]thymidine incorporation. The data shown are expressed as 
the mean ± SE and were obtained from fi ve independent experiments.
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although the expansion of the CD4+CD25+CD45RO+IL-
7Rαhigh cell population in patients with chronic rejection was 
associated with a decrease of T reg cells, the reduction of the 
T reg cell population was not suffi  cient to explain the in-
crease of the CD4+CD25+CD45RO+IL-7Rαhigh cell popu-
lation, thus indicating an absolute increase in the number 
of this latter population. Indeed, the absolute number of 
CD4+CD25+CD45RO+IL-7Rαhigh cells was also signifi -
cantly increased (1.5 ± 0.4 × 103 cells per 100 μl of blood) 
in patients with chronic rejection compared with stable trans-
plant recipients (0.8 ± 0.1 × 103 cells per 100 μl of blood; 
P = 0.04). However, the absolute number of T reg cells did 
not signifi cantly change between the stable transplant recipi-
ents (3.8 ± 0.5 × 103 cells per 100 μl of blood) and the pa-
tients with chronic rejection (3 ± 0.5 × 103 cells per 100 μl 
of blood; P = 0.3).
Collectively, these results indicate (a) an association between 
the presence of an expanded CD4+CD25+CD45RO+IL-
7Rαhigh cell population and the occurrence of chronic al-
lograft rejection, and that (b) the expansion of the activated 
CD4+CD25+CD45RO+ cell population defi ned by the ex-
pression of IL-7Rα cannot be explained only by the result 
of the decrease of the T reg cell population defi ned by the 
expression of FOXP3. Therefore, monitoring IL-7Rα may 
be a more valuable tool than monitoring FOXP3 to assess the 
patient’s immune status and/or the occurrence of allograft 
chronic rejection.
The CD4+CD25+CD45RO+IL-7R𝛂high cell population 
contains allospecifi c CD4 T cells
To have insights on the possible involvement of the 
CD4+CD25+CD45RO+IL-7Rαhigh cell population in the 
allospecifi c response to the graft, we examined the allospecifi c 
response of the transplant recipient to the donor in a MLR. 
Indeed, we had the opportunity to address this issue in a case 
of documented kidney chronic humoral rejection in which 
blood mononuclear cells of the (living) donor were available. 
The CD4+CD25+CD45RO+IL-7Rαhigh cell population was 
largely expanded (40% of the CD4+CD25+ T cells) at the 
time of the diagnosis of chronic humoral rejection (time point 1; 
Fig. 3). The MLR was performed using the transplant 
 recipient–sorted CD4+CD25+CD45RO+IL-7Rαhigh cells 
mixed with irradiated transplant donor or MHC unrelated 
blood mononuclear cells. Interestingly, we found that the 
proliferation of the CD4+CD25+CD45RO+IL-7Rαhigh cell 
population was substantially higher (stimulation index [SI] = 66) 
in the presence of irradiated transplant donor blood mono-
nuclear cells compared with the proliferation in the presence 
of MHC unrelated blood mononuclear cells (SI = 13; Fig. 3). 
Because of the diagnosis of chronic humoral rejection, this 
Figure 2. Expression of CD25, CD45RO, IL-7R𝛂, and FOXP3 on 
blood CD4 T cells of stable transplant recipients and kidney trans-
plant recipients with chronic rejection. Blood mononuclear cells from 
32 stable transplant recipients (11 kidney and 21 liver transplant recipients) 
and 4 kidney transplant recipients with biopsy-proven chronic rejection were 
analyzed for the surface expression of CD4, CD25, CD45RO, and IL-7Rα 
and for the intracellular expression of FOXP3. (A) Means ± SE of cumulative 
data on the proportion of CD4+CD25+ T cells in stable transplant recipi-
ents and transplant recipients with chronic rejection. The percentage 
of CD4+CD25+ T cells in total CD4+ T cells was slightly increased in 
transplant recipients with chronic rejection compared with stable trans-
plant recipients, but these differences were not signifi cant (P = 0.21). 
(B) Means ± SE of cumulative data on the proportion of CD4+CD25+
FOXP3+IL-7Rαlow T cells in stable transplant recipients and transplant 
recipients with chronic rejection. The proportion of FOXP3+IL-7Rαlow T cells 
within the CD4+CD25+ T cell population was slightly reduced in the pa-
tients with chronic rejection compared with stable transplant recipients, 
and these differences were significant (P = 0.01).(C) Means ± SE of 
cumulative data on the proportion of CD4+CD25+CD45RO+IL-7Rαhigh 
T cells in stable transplant recipients and transplant recipients with chronic 
rejection. The proportion of CD45RO+IL-7Rαhigh T cells within the 
CD4+CD25+ T cell population was signifi cantly increased in the chronic 
rejection group compared with the stable group (P < 0.0001).
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patient was treated with high-dose (2 g/kg) i.v. Ig admin-
istration therapy. We had the opportunity to reassess the 
expansion of the CD4+CD25+CD45RO+IL-7Rαhigh cell 
population 15 mo after the fi rst determination (time point 1) 
and 2 mo after treatment with i.v. Ig therapy. At this time 
(time point 2), the IL-7Rαhigh cell population had decreased 
to 20% of the CD4+CD25+ T cells, which corresponded to a 
reduction of 50% compared with time point 1 (before the 
i.v. Ig therapy). At time point 2, we also analyzed the allospe-
cifi c response mediated by the recipient-sorted CD4+CD25+
CD45RO+IL-7Rαhigh cells in a MLR with irradiated donor 
or MHC unrelated blood mononuclear cells. As shown at time 
point 2 in Fig. 3, there was no more evidence of an allospecifi c 
response against the transplant donor–specifi c cells (SI = 1.13), 
whereas the proliferative response against the MHC unrelated 
blood mononuclear cells remained unchanged compared with 
time point 1. Therefore, we observed an association between 
the magnitude of the expansion of the IL-7Rαhigh–activated 
cell population and the ability to mediate allospecifi c response 
in vitro. Moreover, these results suggested that i.v. Ig admin-
istration may lead to a decrease (in percentage and function) 
in the IL-7Rαhigh–activated cell population.
In support of the association between the magnitude of 
the IL-7Rαhigh–activated cell population and allospecifi c 
function, we analyzed the allospecifi c response of the IL-
7Rαhigh cell population in two additional cases of stable kid-
ney transplant recipients in which blood mononuclear cells of 
the (living) donors were available. The percentage of the IL-
7Rαhigh cell population was in the range of 20% (16.8 and 
22.2%) in the two cases, and in agreement with the data 
shown for time point 2 in Fig. 3, allospecifi c responses were 
not detected (unpublished data).
Furthermore, to better characterize the infl uence of  immuno-
suppressive therapy on the IL-7Rαhigh cell population, we 
studied fi ve additional transplant recipients and seven subjects 
with various autoimmune diseases receiving immunosuppres-
sive therapy. An augmentation of immunosuppressive ther-
apy in the transplant recipients was consistently associated 
with a signifi cant subsequent reduction in the percentage of 
the IL-7Rαhigh cell population from 31.17 ± 6.33% to 17.33 ± 
4.98% (P = 0.002). The percentage of this population in pa-
tients with autoimmune diseases (n = 7) receiving various types 
of immunosuppressive therapy was not signifi cantly diff erent 
from the one of healthy subjects (P = 0.39; unpublished data).
CD4+CD25+IL-7R𝛂+ cells infi ltrate the allograft
We investigated the phenotype of the cells infi ltrating the 
kidney tissue allograft in fi ve patients with a documented 
diagnosis of chronic humoral rejection. For this purpose, fro-
zen kidney biopsies were simultaneously stained with the 
 following antibody combinations: CD4 plus CD25, CD4 
plus IL-7Rα, CD25 plus IL-7Rα, CD4 plus FOXP3, IL-
7Rα plus FOXP3, and CD25 plus FOXP3. Variable num-
bers of cells infi ltrating the allograft were consistently found 
in all of the cases studied. Of interest, with regard to CD4 
T cells, 20% were CD25+ and 50% were IL-7Rα+; all 
CD25+ cells coexpressed IL-7Rα (Fig. 4 A). The estimates 
of the percentage of infi ltrating CD4+CD25+ and CD4+ IL-
7Rα+ cells have been generated from counting 80 infi ltrat-
ing CD4 T cells in 18 diff erent microscopic fi elds of the fi ve 
kidney biopsies. We also investigated the expression of 
FOXP3 in the CD4 T cells infi ltrating the allograft, but 
CD4+FOXP3+ cells were not found in the fi ve kidney bi-
opsies examined (Fig. 4 B). However, CD4+FOXP3+ cells 
were consistently found in the lymph node biopsies used as 
control tissue (Fig. 4 C). It is also worth mentioning that cel-
lular infi ltrates were very scarce in the biopsy of patients with 
a kidney disease such as interstitial nephritis, and in this case, 
infi ltrating CD4 T cells were CD25− and IL-7Rα− (unpub-
lished data). Therefore, these results indicate that the pre-
dominant CD4 T cell population infi ltrating the allograft in 
patients with chronic rejection is composed of CD4+CD25+ 
and CD4+IL-7Rα+cells.
Importance of the analysis of the CD4+CD25+CD45RO+
IL-7R𝛂high cell population in the clinical monitoring 
of transplant recipients
In this study, the results shown in Figs. 1 and 2 demonstrating 
the expansion in blood of the CD4+CD25+CD45RO+IL-
7Rαhigh cell population were obtained from a cross-sectional 
analysis performed in 32 (21 liver and 11 kidney) organ trans-
plant recipients. We recently had the opportunity to prospec-
tively monitor the CD4+CD25+CD45RO+IL-7Rαhigh cell 
population during the fi rst year after transplantation in 11 
kidney recipients receiving calcineurin-based immunosup-
pression with tacrolimus and mycophenolate mofetil (Fig. 5). 
Figure 3. Analysis of allospecifi c CD4 T cell responses. Sorted puri-
fi ed CD4+CD25+CD45RO+IL-7Rαhigh T cells (7 × 104 cells) from two time 
points of a kidney transplant recipient with biopsy-proven chronic rejection 
were co-cultured with 105 irradiated blood mononuclear cells (40 Gy) either 
from the organ donor or from an MHC unrelated subject. After 7 d of cul-
ture, cell proliferation was measured by [3H]thymidine incorporation. Cell 
cultures containing only irradiated cells were used as negative controls.
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Figure 4. CD4+IL-7R𝛂+ T cells infi ltrate the tissue allograft. Frozen 
kidney biopsies from transplant recipients with chronic rejection were 
stained with IL-7Rα and CD4 or CD25. (A, top) IL-7Rα+ T cells (green) and 
CD4+ T cells (red) are indicated by the arrowheads and are present in the 
interstitial compartment. Double-positive CD4+IL-7Rα+ T cells (yellow 
arrowheads) are colored in orange as a result of the merging of the two 
single-color images. (middle) IL-7Rα+ T cells (green) and CD25+ T cells 
(red) are also present in the interstitial compartment. Double-positive 
CD25+IL-7Rα+ T cells (yellow arrowheads) are colored in orange as a 
At study entry (before transplantation), there were no diff er-
ences in the percentage of CD4+CD25+CD45RO+IL-
7Rαhigh cells between the transplant recipients and living 
donors. The mean percentage in transplant recipients (5.04 ± 
0.75%) and in living donors (4.65 ± 0.7%) was consistent 
with that observed in the large cohort of healthy subjects 
(n = 45; 6.16 ± 0.76%; Fig. 5). Of interest, the 
CD4+CD25+CD45RO+IL-7Rαhigh cell population was sig-
nifi cantly increased (up to 14% of the CD4+CD25+ 
T cells; P < 0.005) 1 mo after transplantation as compared 
with study entry, and the activated cell population remained 
expanded during the year of observation (Fig. 5). Interest-
ingly, kidney allograft function in these recipients was stable 
during the study period, and there was no evidence of al-
lograft rejection. These data further support the relationship 
between the expansion of the IL-7Rαhigh CD4 T cell popu-
lation and the presence of the allograft and the usefulness of 
implementing the determination of this cellular marker in the 
immunologic monitoring of the transplant recipients.
C O N C L U S I O N S 
We have identifi ed the presence of a CD4 T cell population 
that is selectively expanded in patients after organ transplanta-
tion and is phenotypically defi ned by the expression of CD25, 
CD45RO, and high levels of IL-7Rα. Of interest, this cell 
population is expanded in stable transplant recipients in the 
absence of measurable circulating anti-HLA antibodies, thus 
indicating that it represents an allospecifi c cellular marker to 
monitor the immune response against the allograft. More im-
portantly, this cell population contains allospecifi c CD4 T 
cells, it is substantially more expanded in patients with docu-
mented chronic humoral rejection, and 50% of the CD4 T 
cells infi ltrating the allograft (in the case of chronic rejection) 
are IL-7Rα+. Collectively, these results suggest that the 
CD4+CD25+IL-7Rα+ cell population represents a valuable, 
sensitive, and specifi c marker to monitor allospecifi c CD4 T 
cell responses in blood and tissue after organ transplantation. 
The precise contribution of this activated T cell population 
on the induction of eff ector mechanisms of late, chronic al-
lograft rejection (e.g., production of alloantibodies with local 
complement activation) remains to be further studied. The 
clinical usefulness of this novel cellular marker in the moni-
toring of allograft recipients and its relationship with clinical 
outcomes need to be investigated in large prospective cohort 
studies of organ transplant recipients.
MATERIALS AND METHODS
Patients. 21 liver and 15 kidney transplant recipients were studied at the 
Centre Hospitalier Universitaire Vaudois. All patients gave informed written 
consent before participating in the study, which was approved by the local 
institutional review board. 45 healthy volunteers were included as controls.
Peripheral blood was obtained from 21 clinically stable liver transplant 
recipients, all of whom had received a fi rst cadaveric graft and were studied 
for >12 mo after transplantation. This group was composed of 15 males and 
6 females, with a median age of 51.2 yr (range = 20–67 yr) at the time of the 
study and a median time from transplantation to the study of 7.6 yr (range = 
1–19 yr). Their immunosuppressive therapy was based on cyclosporine or 
tacrolimus with prednisone (n = 7) in combination with mycophenolate 
mofetil or azathioprine (n = 2) .
Peripheral blood was also obtained from 15 kidney transplant recipients 
divided into two groups: (a) 11 patients with a stable graft function defi ned by 
a stable serum creatinine with values inferior to 150 μmol/liter and by a 24-h 
proteinuria inferior to 0.5 g/day, and (b) 4 patients with biopsy-proven chronic 
rejection. The stable kidney group was composed of seven males and four 
 females, with a median age of 48.8 yr (range = 24–70 yr) at the time of the study 
and a median time from transplantation to the study of 8.6 yr (range = 1–19 yr). 
All patients had received a fi rst graft: eight from a deceased donor, two from a 
Figure 5. Rapid expansion of the CD4+CD25+CD45RO+IL-7R𝛂high 
cell population after transplantation. Means ± SE of cumulative data 
on the proportion of the CD4+CD25+CD45RO+IL-7Rαhigh T cell population 
in transplant recipients before and up to 1 yr after transplantation. At the 
baseline (before transplantation), recipients and donors have a similar 
proportion of CD4+CD25+CD45RO+IL-7Rαhigh T cells. The IL-7Rαhigh CD4 
T cell population is already signifi cantly increased 1 mo after transplanta-
tion in the transplant recipients and remains expanded for up to 1 yr. 
result of the merging of the two single-color images. (bottom) CD25+ 
T cells (green) and CD4+ T cells (red). Double-positive CD4+CD25+ T cells 
(yellow arrowheads) are colored in orange as a result of the merging of 
the two single-color images. (B, top) CD4+ T cells (green) infi ltrating the 
kidney of a patient with documented chronic rejection are FOXP3 nega-
tive (red). (middle and bottom) CD25+ T cells (green) and IL-7Rα+ T cells 
(green) are also negative for FOXP3 (red). (C) CD4+ T cells (yellow) in the 
lymph node are FOXP3 positive (green). Bars, 10 μm.
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living/related donor, and one from a living/unrelated donor. No patient in 
this group had circulating anti-HLA antibodies. The chronic rejection group 
was composed of two males and two females, with a median age of 42.8 yr 
(range = 26–56 yr) at the time of the study and a median time from transplan-
tation to the study of 9 yr (range = 6–16 yr). Also in this group, patients had 
received a fi rst graft: three from a deceased donor and one from a living/ 
related donor (father to daughter). In the four patients with biopsy-proven 
chronic rejection (29, 30), circulating donor-specifi c anti-HLA antibodies 
(DSA) were detected in serum by ELISA (One Lambda, Inc.), and capillary 
C4d deposits were demonstrated in kidney graft biopsies. In three out of four 
biopsies, typical lamination with multilayering of the basement membrane of 
peritubular capillaries was also demonstrated by electron microscopy. In the 
living/donor recipient with chronic rejection, a repeat B cell cross match was 
positive (T and B cell cross matches were negative at the time of transplanta-
tion). In all four patients, circulating DSA were directed against defi ned class II 
antigens (anti–class II DSA). The median serum creatinine at the time of diag-
nosis of chronic rejection was 247 μmol/liter (range = 184–350 μmol/liter), 
whereas the median 24-h proteinuria was 2.1 g/day (range = 1–3.5 g/day).
A second group of 11 kidney transplant recipients was monitored pro-
spectively at the Hôpitaux Universitaires de Genève and was composed of 
7 males and 4 females, with a median age of 42.7 yr (range = 23–81 yr) at 
the time of the transplantation. The group of kidney donors (living donors) 
was composed of two males and nine females, with a median age of 52.8 yr 
(range = 32–73 yr) at the time of the donation. All of these 11 kidney trans-
plant recipients received a 3–4-d thymoglobulin (1.5 mg/kg) course as in-
duction therapy, with a calcineurin-based immunosuppressive regimen.
The group of patients with various autoimmune diseases studied at the 
Centre Hospitalier Universitaire Vaudois was composed of one male and six 
females, with a median age of 37.9 yr (range = 21–55 yr) at the time of the 
study. The patients received various regimens of immunosuppressive drugs.
FACS analysis and sorting. Peripheral blood mononuclear cells were iso-
lated using standard Ficoll-Hypaque (GE Healthcare) gradient centrifugation. 
The antibodies used for fl ow cytometric analyses included PerCP, PerCP-
Cy5.5, or PE-conjugated mouse anti–human CD4 (Becton Dickinson); allo-
phycocyanin (APC)-conjugated mouse anti–human CD25 (BD Biosciences), 
FITC (BD Biosciences), or ECD (Beckman Coulter)-conjugated mouse anti–
human CD45RO; and PE (Beckman Coulter)- or APC (R&D Systems)-
 conjugated mouse anti–human IL-7Rα. For intracellular FOXP3 analysis, cell 
preparations were fi xed and permeabilized with fi xation/permeabilization 
buff ers (eBioscience) after staining of cell surface markers and stained with 
FITC-conjugated rat anti–human FOXP3 (eBioscience). For cell sorting 
experiments, CD4+CD25+CD45RO+IL-7Rαlow, CD4+CD25+CD45RO+
IL-7Rαhigh, and CD4+CD25− cell populations were isolated from the peripheral 
blood of transplant recipients. The grade of purity in all of the sorting experi-
ments ranged between 92 and 98%. All fl ow cytometric analyses were per-
formed on a FACSCalibur and LSRII, while cell sorting was performed on a 
FACSVantage SE and FACSAria (Becton Dickinson).
Suppressive function assay. The suppressive function of freshly sorted 
CD4+CD25+CD45RO+IL-7Rαlow and CD4+CD25+CD45RO+IL-7Rαhigh 
cells isolated from the peripheral blood of liver transplant recipients was 
assessed in a MLR.
For these purposes, 105 irradiated (40 Gy) allogeneic blood mononuclear 
cells (stimulator cells) and 5 × 104 CD4+CD25− T cells isolated from liver 
transplant recipients (responder cells) were co-cultured either alone (positive 
control) or in the presence of 5 × 104 freshly sorted CD4+CD25+CD45RO+IL-
7Rαlow or CD4+CD25+CD45RO+IL-7Rαhigh cells. Proliferation was mea-
sured at day 7 by [3H]thymidine incorporation.
Allospecifi c T cell response. Allospecifi c T cell proliferation of the 
CD4+CD25+CD45RO+IL-7Rαhigh cells isolated from one kidney recipient 
with documented chronic rejection was assessed by co-culturing 105 irradi-
ated (40 Gy) donor blood mononuclear cells with 7 × 104 sorted purifi ed 
recipient CD4+CD25+CD45RO+IL-7Rαhigh cells. Cultures were made in 
triplicates, and proliferation was measured at day 7 by [3H]thymidine incor-
poration. As a control, the same sorted purifi ed population was co-cultured 
with irradiated MHC unrelated blood mononuclear cells. The SI was calcu-
lated on the basis of the fold increase in the proliferation observed in the cul-
ture containing CD4+CD25+CD45RO+IL-7Rαhigh cells and irradiated 
donor or MHC unrelated cells compared with the negative control, i.e., 
cultures containing irradiated cells alone.
Cytokine production. 2 × 106 cryopreserved blood mononuclear cells 
from liver and kidney transplant recipients were prestained with anti–IL-
7Rα PE and mouse anti–human CD25 PE-Cy7 (BD Biosciences) anti-
bodies and stimulated overnight with soluble 1 μg/ml anti-CD3 plus 1 μg/ml 
anti-CD28 antibodies (BD Biosciences) in 1 ml of complete medium (RPMI 
plus 10% FBS) containing 1 μl/ml each of GolgiPlug and GolgiStop (BD 
Biosciences). At the end of the stimulation period, the cells were washed and 
stained with CD4 PerCP-Cy5.5 and CD45RO ECD antibodies. The cells 
were permeabilized with FACS Permeabilizing Solution 2 (BD Biosciences) 
and stained with mouse anti–human IFN-γ or TNF-α FITC and rat anti–
human IL-2 APC (BD Biosciences). Data were acquired on an LSRII and 
analyzed using DiVa software (Becton Dickinson). Unstimulated cells were 
used as negative control for the production of cytokines. The background 
never exceeded 0.02%.
Immunohistochemistry. Frozen tissues from kidney biopsies were incu-
bated at room temperature for 20 min with a blocking solution (5% normal 
goat serum) and immediately stained overnight at 4°C with a mix of primary 
antibodies: IgG1 mouse anti–human IL-7Rα (BD Biosciences) with IgG2a 
mouse anti–human CD4 (Beckman Coulter) or with IgG2b rat anti–human 
CD25 (Serotec) and mouse anti–human CD4 with rat anti–human CD25. 
The tissues were also stained with IgG2a rat anti–human FOXP3 (eBioscience) 
and IgG1 mouse anti–human CD4 (BD Biosciences) or IgG1 mouse anti–
human CD25 (BD Biosciences) or mouse anti–human IL-7Rα. Secondary 
antibodies (goat IgG specifi c) were added after 16 h (after washing the un-
bound primary antibodies) and incubated for 1 h at room temperature in the 
dark. Goat anti–mouse IgG1 Alexa Fluor 488, goat anti–mouse IgG2a Alexa 
Fluor 594, goat anti–mouse IgG (H+L) Alexa Fluor 532, goat anti–rat IgG 
(H+L) FITC, biotinylated goat anti–rat IgG (H+L), streptavidin Texas red, 
and streptavidin FITC were all obtained from Invitrogen. The tissues were 
mounted with antifade reagent (ProLong Gold; Invitrogen) and observed on 
an imaging microscope (Axioplan 2; Carl Zeiss MicroImaging, Inc.) with 
epifl uorescence using single-band excitation fi lters: Alexa Fluor 488, ex. 
480/40 LP; Alexa Fluor 594, ex. 546/12; and Alexa Fluor 532, ex.535. 
Photos were taken using an AxioCam and AxioVision software (version 4.6; 
Carl Zeiss MicroImaging, Inc.). Each fl uorochrome was imaged separately, 
and the resulting images were automatically pseudocolored and merged by 
the AxioVision software.
Statistical analysis. Statistical signifi cance was calculated by the two-tailed 
t test and linear regression analysis. P < 0.05 was considered signifi cant.
Online supplemental material. Fig. S1 shows that CD4+CD25+CD45RO+
IL-7Rαhigh cells secrete infl ammatory cytokines. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20062120/DC1.
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